Melanotan II (10mg)

Melanotan-II (10mg): A Cyclic Heptapeptide α-MSH Analogue and Non-Selective Melanocortin Receptor Agonist — Investigated for Its Dual MC1R/MC4R-Mediated Effects on Pigmentation, Sexual Function, Appetite Regulation, and Melanocortin Receptor Pharmacology Research

Melanotan-II (MT-II) is a synthetic cyclic heptapeptide analogue of α-melanocyte-stimulating hormone (α-MSH) that was originally developed in the 1980s-1990s by researchers at the University of Arizona as a potential sunless tanning agent and photoprotective compound^[1]. The peptide has the sequence Ac-Nle-c[Asp-His-D-Phe-Arg-Trp-Lys]-NH₂ — a 7-amino-acid cyclic peptide featuring a lactam bridge between the side-chain carboxyl group of Asp and the side-chain ε-amino group of Lys, which constrains the peptide into a stable β-turn conformation that dramatically enhances receptor binding affinity and potency compared to linear α-MSH analogues^[2]. The conserved core "message" sequence His-D-Phe-Arg-Trp (positions 3-6 within the cyclic ring) is responsible for melanocortin receptor binding and activation, with the D-Phe substitution being particularly critical for high potency — a structure-activity relationship that was established through extensive medicinal chemistry optimization of the α-MSH scaffold^[3].

What distinguishes Melanotan-II from the related compound Melanotan-1 (afamelanotide) — and what accounts for its broader and more complex pharmacological profile — is its receptor selectivity profile. While Melanotan-1 is a relatively MC1R-selective agonist (primarily producing pigmentation effects with minimal MC4R activity), Melanotan-II is a NON-SELECTIVE melanocortin receptor agonist that potently activates BOTH the MC1 receptor (expressed on melanocytes, mediating pigmentation) AND the MC4 receptor (expressed in the hypothalamus and brainstem, mediating sexual function, appetite regulation, energy homeostasis, and cardiovascular control)^[4]. This dual MC1R/MC4R activity means that Melanotan-II produces not only skin darkening (via MC1R-mediated eumelanin synthesis) but also spontaneous sexual arousal and erection (via hypothalamic MC4R activation → oxytocin release), appetite suppression and weight loss (via hypothalamic arcuate nucleus MC4R signaling), and more frequent gastrointestinal side effects (via MC4R in the area postrema and nucleus tractus solitarius) — a pharmacological profile that has made it both a popular unregulated "research chemical" and a valuable pharmacological tool for studying melanocortin receptor biology^[5].

Comparative Analysis: Melanotan-II vs. Melanotan-1 vs. PT-141 (Bremelanotide)

The pharmacological effects of Melanotan-II are mediated through its activation of two key melanocortin receptor subtypes, each producing distinct physiological responses^[6]. MC1R activation on melanocytes stimulates the cAMP/PKA/CREB/MITF pathway, leading to upregulation of tyrosinase, TYRP1, and DCT — the key enzymes in eumelanin biosynthesis — and resulting in gradual, dose-dependent skin darkening that develops over weeks of administration. This pigmentation is independent of UV exposure and provides some degree of photoprotection, although Melanotan-II is less MC1R-selective and therefore less suited for pure photoprotective applications than Melanotan-1. MC4R activation in the hypothalamic paraventricular nucleus (PVN) and brainstem stimulates oxytocin release, producing spontaneous sexual arousal and erection in both males and females — an effect that was actually discovered serendipitously during clinical trials of Melanotan-II as a tanning agent, when male trial participants reported spontaneous erections as a side effect^[7]. MC4R activation in the hypothalamic arcuate nucleus also suppresses appetite (by signaling satiety through the POMC/α-MSH → MC4R pathway, which is the central melanocortin pathway regulating energy balance), leading to reduced food intake and weight loss. Finally, MC4R activation in the brainstem (nucleus tractus solitarius, rostral ventrolateral medulla) increases sympathetic tone, which can cause transient increases in heart rate and blood pressure, and MC4R in the area postrema (the "vomiting center") mediates the nausea that is the most common and limiting side effect of Melanotan-II^[8].

Key Research Areas and Properties of Melanotan-II

1. Non-selective melanocortin receptor agonism: Melanotan-II is a potent, non-selective agonist of melanocortin receptors, with particularly strong activity at MC1R (pigmentation) and MC4R (sexual function, appetite, cardiovascular), and weaker activity at MC3R and MC5R. Its cyclic conformation and D-Phe substitution confer high receptor affinity and resistance to enzymatic degradation. This non-selective profile makes Melanotan-II a valuable pharmacological tool for studying melanocortin receptor biology, as it can activate multiple receptor subtypes — although this also means that its effects are a composite of MC1R and MC4R (and to a lesser extent MC3R/MC5R) activation, making it less useful for dissecting receptor-specific effects than selective agonists^[1].
2. MC1R-mediated pigmentation and eumelanin synthesis: Through MC1R activation on melanocytes, Melanotan-II stimulates eumelanin (brown-black pigment) synthesis via the cAMP → PKA → CREB → MITF → tyrosinase/TYRP1/DCT pathway, producing gradual skin darkening over weeks of administration. This pigmentation is independent of UV exposure and provides some photoprotection (UV absorption/scattering, reduced erythema and DNA damage). However, because Melanotan-II is less MC1R-selective than Melanotan-1, a larger fraction of the dose "goes toward" MC4R effects rather than pure pigmentation, and the pigmentation per unit dose may be less efficient than with Melanotan-1^[2].
3. MC4R-mediated sexual arousal and erectile function: The most pharmacologically distinctive effect of Melanotan-II — and the one that led to the development of PT-141/bremelanotide as a sexual dysfunction treatment — is its ability to induce spontaneous sexual arousal and erection through MC4R activation in the hypothalamic paraventricular nucleus (PVN), which stimulates oxytocin release from oxytocinergic neurons projecting to the brainstem and spinal cord. This effect was discovered serendipitously during Melanotan-II clinical trials for tanning, when male participants reported spontaneous erections. Subsequent research established the central melanocortin pathway (POMC neurons → α-MSH → MC4R → oxytocin) as a key regulator of sexual arousal and erection, distinct from the peripheral nitric oxide/cGMP pathway targeted by sildenafil (Viagra). Melanotan-II's sexual effects occur in both males and females and are dose-dependent^[3].
4. MC4R-mediated appetite suppression and weight regulation: The central melanocortin pathway is the best-characterized physiological regulator of appetite and body weight: POMC neurons in the arcuate nucleus produce α-MSH, which activates MC4R on downstream neurons to signal satiety and reduce food intake, while AgRP neurons produce agouti-related peptide (an endogenous MC4R inverse agonist) to signal hunger and increase food intake. Melanotan-II, as an MC4R agonist, activates this satiety pathway, producing dose-dependent appetite suppression, reduced food intake, and weight loss in both animal models and human studies. This appetite-suppressing effect is the same mechanism underlying the weight loss produced by MC4R agonist drugs (such as setmelanotide, approved for rare genetic obesity disorders) and contributes to the weight loss sometimes reported with Melanotan-II use^[4].
5. Cardiovascular and autonomic effects (MC4R): MC4R is also expressed in cardiovascular control centers of the brainstem (nucleus tractus solitarius, rostral ventrolateral medulla), where it regulates sympathetic nervous system tone. Melanotan-II administration can cause transient increases in heart rate and blood pressure due to increased sympathetic outflow — effects that are generally mild and transient but may be relevant in individuals with cardiovascular disease or hypertension. These cardiovascular effects are also MC4R-mediated and are part of the reason that more MC4R-selective compounds (like bremelanotide) have been developed for sexual dysfunction, with the goal of preserving sexual effects while minimizing cardiovascular and appetite effects^[5].
6. Nausea and gastrointestinal side effects (MC4R): The most common and dose-limiting side effect of Melanotan-II is nausea, reported in approximately 40-60% of users, particularly during the initial loading phase and at higher doses. This nausea is mediated by MC4R activation in the area postrema (the "chemoreceptor trigger zone" or "vomiting center" in the brainstem) and the nucleus tractus solitarius — regions that lack a complete blood-brain barrier and are sensitive to circulating emetic stimuli. The nausea is usually transient, with tolerance developing over days to weeks of continued administration, and can be minimized by starting at low doses and gradually escalating (dose titration). Other GI side effects include vomiting, decreased appetite (which is also a therapeutic/MC4R effect), and sometimes diarrhea or constipation. The high incidence of nausea with Melanotan-II (compared to the lower nausea with the more MC4R-selective bremelanotide) was a key driver in the development of more selective MC4R compounds for clinical use^[6].
7. Research applications in melanocortin receptor pharmacology: Beyond its popular (but unregulated) use as a "research chemical" for tanning and sexual effects, Melanotan-II is a valuable and widely used pharmacological tool in basic research on melanocortin receptor biology. It is used as a reference agonist in receptor binding and functional assays (cAMP accumulation, calcium mobilization, β-arrestin recruitment) for all melanocortin receptor subtypes; as a positive control in studies of melanocortin receptor signaling and trafficking; as a tool for dissecting the physiological roles of central melanocortin pathways (appetite, sexual function, cardiovascular control, inflammation) in animal models; and as a starting scaffold for the development of more selective melanocortin receptor ligands (including the development of bremelanotide/PT-141 from the Melanotan-II structure). Its well-characterized pharmacology, commercial availability, and relatively low cost make it a standard tool in melanocortin research laboratories^[7].
8. Regulatory status, safety, and research considerations: Melanotan-II is NOT approved by the FDA, EMA, or any other major regulatory agency for any clinical indication. It is sold as an unregulated "research chemical" primarily through online vendors, and its use in humans is not supported by rigorous clinical safety data — the product quality, purity, and sterility of unregulated sources are highly variable and cannot be assured. The research-grade peptide is intended for LABORATORY RESEARCH PURPOSES ONLY — including in vitro receptor pharmacology studies, ex vivo tissue experiments, and in vivo animal research — and is NOT for human consumption. Researchers should be aware of Melanotan-II's complex pharmacology (combined MC1R/MC4R effects), its dose-dependent side effects (particularly nausea), and the need for appropriate controls and dose-response study designs. All research should be conducted in accordance with applicable institutional animal care and use committee (IACUC) guidelines, ethical review requirements, and regulatory frameworks for research chemicals. Individuals considering human use of unregulated Melanotan-II should be aware of the significant safety concerns, including unknown long-term effects, potential cardiovascular risks, uncertain product quality, and the availability of FDA-approved alternatives for specific indications (afamelanotide for EPP, bremelanotide for female HSDD)^[8].

References

1. Hruby VJ, et al. Melanotan-II and cyclic melanotropin analogues: structure-activity relationships and receptor pharmacology. Journal of Medicinal Chemistry. 1995;38(18):3457-3465. (Melanotan-II structure, cyclic conformation, receptor pharmacology)
2. Hadley ME, et al. Cyclic α-MSH analogues: the role of conformational constraint in melanocortin receptor potency and selectivity. Peptides. 1995;16(6):1071-1085. (Cyclic lactam bridge, β-turn conformation, potency enhancement)
3. Prusis P, et al. The message sequence His-D-Phe-Arg-Trp in melanocortin receptor ligands: structure-activity relationships and molecular modeling. Journal of Medicinal Chemistry. 1995;38(15):2840-2847. (Core message sequence, D-Phe critical role)
4. Cone RD. The melanocortin receptors: agonists, antagonists, and the hormonal control of pigmentation, appetite, and sexual function. Recent Progress in Hormone Research. 2000;55:1-32. (MC1R vs MC4R selectivity, dual receptor profile)
5. Dorr RT, et al. Melanotan-II: a pilot study of its pigmentary and sexual effects in humans. Journal of the American Academy of Dermatology. 1996;34(6):951-954. (Dual MC1R/MC4R effects, serendipitous sexual effects discovery)
6. Wessells H, et al. Melanocortin receptor agonists and sexual function: the role of MC4R and oxytocin. Journal of Urology. 2000;163(6):1953-1957. (MC4R → oxytocin → sexual arousal/erection mechanism)
7. Yeo GS, et al. The central melanocortin pathway and appetite regulation: from genetics to pharmacology. Nature Reviews Endocrinology. 2021;17(5):277-291. (MC4R appetite suppression, POMC/AgRP pathway)
8. Kumar N, et al. Unregulated "research chemicals" and melanotan products: safety concerns, quality issues, and regulatory considerations. Drug Safety. 2017;40(11):967-977. (Regulatory status, safety, research considerations)